Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I have 8 mil or so
I need some funds to free up to even my holdings here out to 10 mil. Then they can take TEMN to $1!!!!!!!!!!
LOL! Just say no!!
Nice, I didn't even look thinking it was same news as yesterday. Going to see some movement continuing!
I'm ready!
No but that 5k sell was mine. Time for me to bite the bullet on dumping this scam. I removed my AON on my sell order and the scumbags sold only 5k and dropped it on me.
Do I get charged a full commission if they sell 1% of my order by the EOB?
If something ever does happen, kudos to you all for keeping it up there on the breakout boards.
If the company is diluting, they are pretty stupid to NOT put out some PRs cause folks notice the % gain in the breakout boards. It would run with new blood from a PR!
I wonder what the wait time is for a name change and new business model on this POS.
Gonna finish at HOD today! watch...
Nice! Moving forward. We will break $1 in 2012!
CEL- SCI Corp. Updates Phase III Clinical Activities for Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Inj...
http://ih.advfn.com/p.php?pid=nmona&article=50338062&symbol=CVM
CEL- SCI Corp. Updates Phase III Clinical Activities for Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Inj..
CEL- SCI Corp. Updates Phase III Clinical Activities for Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Inj...
Print
Alert
Cel Sci (AMEX:CVM)
Intraday Stock Chart
Today : Wednesday 7 December 2011
CEL-SCI Corporation (NYSE AMEX: CVM) provided an update today of the progress of its Phase III clinical trial of its investigational therapy Multikine (Leukocyte Interleukin, Injection)*, which is currently being investigated in an open-label, randomized, controlled, multi-center study.
Notable highlights include:
Patients have been enrolled into the Study in all three continents (North America, Europe and Asia).
To date, thirty six (36) clinical centers have met all legal, regulatory, and protocol requirements to screen and enroll patients. Ten of these centers in the study are controlled by CEL-SCI's partners Teva Pharmaceuticals Industries Ltd. (Israel) and Orient Europharma (Taiwan). CEL-SCI anticipates that approximately 15 additional centers will be added for this study.
CEL-SCI is looking to expand the Phase III study to several additional European countries to further accelerate patient enrollment. One of those countries is Croatia, a country in which Teva Pharmaceutical Industries has exclusive marketing rights to sell Multikine.
Dr. Eyal Talor, Chief Scientific Officer of CEL-SCI, has already visited 21 clinical centers around the world and is planning to visit all of the remaining clinical centers in 2012 to help ensure the study quality.
"We are pleased that enrollment in this clinical study has been accelerating,” said Geert Kersten, CEL-SCI's Chief Executive Officer. “This study is designed to prove that Multikine added to the standard of care can increase overall survival of head and neck cancer patients in a statistically significant manner. Everything is being done to complete the study in an efficient and timely manner.”
CEL-SCI’s Phase III study is designed to determine if Multikine (Leukocyte Interleukin, Injection) investigational therapy administered prior to current standard of care (Surgery plus Radiotherapy or Surgery plus Concurrent Radiochemotherapy) used for the treatment naive (yet untreated) subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate (Head and Neck cancer) will result in an increased overall rate of survival versus the subjects treated with standard of care only.
About CEL-SCI Corporation
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also developing (and investigating) an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
y, stickied that!
not me
It may not be today but these prices are cheap.
There goes a <$100 slap on .0149! LOL big players hittin it!
y, thanks to the third party for paying to take a crap here.
Well, there is at least 3 of you touting this one today. Prove your confidence and spend $1k each to get it there.
ICNM news and buzzing this a.m.!
I am here though and that is just bad luck for everyone else. I need to change my alias I have so many bags.
I NEED this to be BIG! Well, at least not a scam.
GO TEMN!!
I'll smack that!
Me too!
Did you mention your concern about the share discrepancy?
Who is that in your signature? I find myself pausing.
thanks, I will.
I don't have PM but ditto that. I am just a regular old schlep with a 9 to 5 and no team. I probably should avoid penny stocks but my personality needs the input.
Unfortunately, that means I am a multi-stock bag-holder.
This one, I am holding some for $20/share or bust!
Not trying to start anything. This needs to more negative pub. .30 good long-term tuck it away though.
That is true. Point taken.
Not anytime soon.
I saw 9:30 this morning and the ask was higher than now all day.
Anyone that bought on the ask after you featured it is in the red today unless they flipped early.
Stop the fluffy math.
One day...
Remove this sticky already. The links don't work.
You know....RAMO Expected Price Per Share .63-$3.09, per PPA's
I'm bored, it was only $20
How about that tap?
What? Are they going to rocket up the ask and nudge the bid by .0005 until they get some sellers?
They need to up that bid!
There's a tap. Tried 150k but they wouldn't fill it but I changed it 100k and it went right away.
Good morning!
Bologne. Just a morning shake-out. Look back at 10:30. Not if, but WHEN they get that first contract...